An observational study in Glaucoma Open-Angle, Glaucoma Eye and Glaucoma; Drugs, sponsored by Dr. Kaweh Mansouri. Enrolling by invitation at 1 site in Switzerland. Open to participants aged 1 Year to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-05.
Sponsored by Dr. Kaweh Mansouri · Observational
The study is an observational analysis of patients' medical data recorded in a large-scale register, both retrospective (for patients operated and data recorded before 2018) and prospective (for data collected after 2018) in nature.Patients' medical data contained in the register will be analysed to determine the efficacy of the treatments they received during their follow-up at the investigation centre.
This study involves the creation and analysis of a large-scale register including all patients suffering from glaucoma, currently and previously followed-up and treated at a single tertiary centre in Lausanne, Switzerland. The design of the study is longitudinal, observational and comparative. Patients are recruited retrospectively if they attended the research centre before September 2018, and prospectively if they attend the centre from this month onwards. Their inclusion does not affect their care, treatment choice or follow-up. All data of recruited patients is be kept in their medical notes until a specific analysis is launched. Data is then exported from their medical notes into a coded database for analysis. At the end of each analysis session (defined as the publication of the related article), all exported data is fully anonymised.
Data analysis will aim to assess the long-term efficacy, safety profile, and factors predictive of success/failure of treatments performed.
To ensure the quality of all included data, health-related information will be extracted directly from the medical notes and coded into the register by a Clinical Research Associate. Conformity of the process and recorded data will be confirmed by regular internal auditing. For quality assurance the Ethics Committee may visit the research sites. Direct access to the source data and all project related files and documents must be granted on such occasions.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.
This study's planned enrollment of 30,000 is above the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Dr. Kaweh Mansouri is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Any patient suffering or suspected of glaucoma and treated at Montchoisi Clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of patients with IOP reduction mmHg
Final Intra Ocular Pressure \<20% compared to baseline
Time frame: 12 month
Patients with quantitative OCT variations ( RNFL, μm)
Variation of RNFL before and after treatment ( laser, surgery, drug..)
Time frame: 12 month
Number of patients with quantitative VF variation ( MD, dB)
Visual Field MD variation before and after treatment ( laser, surgery, drug..)
Time frame: 12 month
Number of patients with quantitative VF variation (LV, dB)
Visual Field MD variation before and after treatment ( laser, surgery, drug..)
Time frame: 12 months
Number of operations received by a patients
Number of operations undertaken by each patient
Time frame: 12 month
Number of patients undergoing a specific ocular surgical or laser procedure
Number of patients undertaking different types of ocular procedures ( deep sclerectomy, cataract, LPI, SLT,...)
Time frame: 12 month
Number of lowering IOP drugs ( molecules) taken by each patient
Number of molecules used by each patient (e.g Cosopt: 2 molecules, Xalatan: 1...)
Time frame: 12 month
Anterior segment OCT variations: ACA (°), SSA (°)
variations of these measurements before and after procedure ( surgery or laser)
Time frame: 12 month
Anterior segment OCT variations: AOD (mm)
variations of these measurements before and after procedure ( surgery or laser)
Time frame: 12 month
Anterior segment OCT variations: TISA (mm2)
variations of these measurements before and after procedure ( surgery or laser)
Time frame: 12 month
Plan to share: Undecided
Started Jan 2019 (actual). Primary completion is estimated for Jan 2030, 132 months after the start.
Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's planned 132 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Kaweh Mansouri